NEUPHORIA THERA. O.N. Aktie

Neuphoria Therapeutics is calling on shareholders to vote for its two board nominees, Peter Miles Davies and David Wilson, as an ongoing strategic review and a dispute with activist investor Lynx1 Master Fund continue. The review was initiated after the failure of the Phase‑3 AFFIRM‑1 study for BNC210; the company is now exploring transactions, partnerships and other options to maximize value. H.C. Wainwright & Co. is acting as financial adviser, Neuphoria is also considering collaborations such as early clinical studies with Merck & Co., and it has implemented a time‑limited shareholder rights plan. » More on de.investing.com

Neuphoria reports that the phase 3 AFFIRM‑1 trial of BNC210 failed to meet the primary endpoint in social anxiety disorder (SAD); secondary endpoints also showed no significant differences. The company is discontinuing development of the SAD program, halting further investment and initiating a strategic review to preserve cash. Neuphoria is evaluating potential next steps for BNC210 in PTSD and cites a partnership with Merck that could still yield up to $450 million in milestone payments. As of June 30, 2025, Neuphoria had $14.2 million in cash, which the company expects will fund operations into the second quarter of 2027. » More on de.investing.com

Neuphoria Therapeutics released on September 29, 2025 the results for the quarter ended June 30, 2024. For the full year the company reports a loss per share of $223.440, after -$0.160 in the prior year. » More on finanzen.net